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Copyright © 2008 AHC Prophet of Pit-1 (Prop1) is an early transcription factor that delays the appearance of
gonadotropin in the developing pituitaries. Prop1 transgenic (Tg) mice have been shown to
generate pituitary tumors that either produce TSH or are non-hormone producing. In our
series of Prop1 Tg mice, only 5 out of 9 female mice produced pituitary adenomas, and the
adenomas were only GH, PRL, GH and PRL, PRL and gonadotropin or TSH producing. The
pituitary cells that surrounded these adenomas showed hyperplasia of the corresponding
hormone producing cells; i.e. the GH cells were increased in the pituitary that contained
GH producing adenoma. In addition, although the adenomas lacked the expression of Prop1,
the non-neoplastic pituitary cells showed expression of Prop1.
The Prop1 Tg mice also showed vacuolated cells with eccentric nuclei, which are charac-
teristic of “signet-ring hypertrophic cells”. Using immunohistochemistry, these signet ring
hypertrophic cells were found to be positive for gonadotropin.
Taken together, our results suggest a (1) tumorigenic effect of Prop1 in the pituitaries, and
(2) causative effects of signet ring-type gonadotropes.
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I. Introduction
The pituitary gland develops from Rathke’s pouch and
its primordium appears on embryonic day (e) 8.5 in mice.
The hormone producing cells of the pituitary gland initially
appear as α-glycoprotein hormone subunit (αGSU) positive
cells on e11 and, subsequently, differentiate into anterior
pituitary hormone producing cells [41]. Pituitary cell types
can be classified into three lineages: the growth hormone
(GH)-prolactin (PRL)-thyroid stimulating hormone (TSH)
(GH-PRL-TSH) cell lineage, the proopiomelanocortin
(POMC; precursor of adrenocorticotropic hormone, ACTH)
lineage, and the gonadotropin (luteinizing hormone/follicle
stimulating hormone; LH/FSH) lineage. Various transcrip-
tion factors have been reported to play roles in the differen-
tiation of these lineages. Differentiation into the POMC
lineage depends on the expression of NeuroD1 and Tpit
[21, 28]. Gata2 [7, 36] and SF1 [16] expression indicate
differentiation into the gonadotropin lineage. The GH-PRL-
TSH lineage, which is regulated by Pit1 [3, 15], is also de-
pendent on the function of the ‘paired’-like homeodomain
transcription factor, Prop1, as indicated by studies in Prop1
mutants (Ames dwarf mutant mice (Prop1df/df) and combined
pituitary hormone deficiency (CPHD) in humans) [1, 8, 31,
43]. Prop1 is an early regulator of Pit1 in the developing
mouse pituitary gland [10]. With maximum expression at
e12.5,  Prop1 mRNA expression rapidly decreases after
e14.5, but may persist at detectable levels in some species
[34]. The temporal regulation of Prop1 gene expression is
critical to its function.
In human pituitary adenomas, transcription factors and
synergistic interactions are involved in the adenomatous
differentiation of the pituitary gland, as well as normal cell
differentiation [27, 32, 37, 39]. Persistent Prop1 express-Egashira et al. 48
ing mice have delayed gonadotrope development and a
propensity for tumorigenesis [6]. It has been reported
that non-functioning tumors or focal thyrotrope hyperplasia
appear in the pituitaries of aged Prop1 transgenic mice.
In order to explore the effects of Prop1 overexpression
on pituitary function, the tumorigenesis and differentiation
rates of pituitary cells from Prop1 transgenic mice were
examined. We identified tumors of the Pit1-dependent cell
lineage. In addition to tumor formation, the appearance of
signet-ring type gonadotropes was observed. This study was
designed to elucidate the roles of Prop1 in tumorigenesis and
its effect on the differentiation of pituitary cells.
II. Materials and Methods
The generation of Prop1 transgenic mice
Mice carrying the Prop1 alleles were supplied by the
University of Michigan Medical School and bred at Tokai
University. Mice were housed in ventilated cages under
12-h light and 12-h dark cycles. All mice were maintained
under specific pathogen-free conditions at Tokai University
School of Medicine (Isehara, Japan), and the experiments
proceeded according to the Guidelines for Animal Experi-
mentation published by the Japanese Association for Labo-
ratory Animal Science (1987). Prop1 transgenic mice were
generated with mouse Prop1 genomic sequences under the
control of the αGSU (Cga) promoter and with splice sites
and polyadenylation sequences from mouse protamine 1 [6].
Six lines of Prop1 transgenic mice were generated (D1–D6).
In the present study, transgenic mice from lines D4 and D6
were bred to C57BL/6J mice. The D4 line of Prop1 trans-
genics was analyzed in detail. The D4 line of Prop1 trans-
genic mice was officially named TgN(Cga-Prop1)D4Sac.
Genomic DNA was prepared from tail biopsies of the new-
born progeny, and PCR was performed to identify mice that
carried the transgene using a Tissue Direct PCR kit (Gen-
Script Corp., Piscataway, NJ). A forward primer located in
the Cga promoter (5'-ATG GCT CCT TCT TTG AGC TTC-
3') and a reverse primer located in the coding sequence of
Prop1 (5'-TCA ACT TTC AGG ATG TTT TGT ATA A-3')
were used for PCR.
Immunohistochemistry of hormones Pit1 and ERa in Prop1 
transgenic mouse pituitaries
The pituitary glands of the Prop1 transgenic mice at 1.5
years of age were fixed overnight in 4% paraformaldehyde
in 0.1 M phosphate buffer pH 7.4 at 4°C. The fixed tissues
were washed in PBS and dehydrated through successively
more concentrated ethanol solutions and finally embedded
in paraffin. Tissue sections of 4 μm thickness were prepared
for hematoxylin and eosin (H&E) staining and immuno-
histochemistry (IHC). For IHC, the slides were dewaxed
and rehydrated before staining. For transcription factor
immunostaining, epitopes were exposed by autoclaving for
5 min in Antigen Retrieval Citra Plus Solution (BioGenex,
San Ramon, CA). Anti-Pit1 rabbit polyclonal antibody
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used
at a 1:100 dilution. Anti-ERα rabbit polyclonal antibody
(Santa Cruz Biotechnology) was used at 1:2000. Anti-Gata2
rabbit polyclonal antibody (Santa Cruz Biotechnology)
was used at 1:200. Anti-Sf1 rabbit polyclonal antibody
(Affinity BioReagents, Golden, CO) was used at 1:1000.
Anti-PRL (NHPP, NIDDK, Bethesda, MD), anti-human GH
(DakoCytomation, Denmark) and anti-αGSU (NHPP)
rabbit antibodies were used at 1:400, 1:400 and 1:200, re-
spectively. Anti-human LHβ (Beckman-Coulter, Fullerton,
CA), anti-human TSHβ (Advanced Immunochemical Inc.,
Long Beach, CA) and anti-human ACTH (DakoCytoma-
tion) monoclonal antibodies were used at 1:200, 1:100 and
1:200, respectively. Sections were incubated with these pri-
mary antibodies for 1 hr at room temperature and then with
biotin-conjugated secondary antibodies (Jackson Immuno-
Research, West Grove, PA). Signals were amplified using
the horseradish peroxidase (HRP) conjugated ENVISION
plus kit (DakoCytomation) according to the manufacturer’s
instructions. HRP activity was visualized with 3,3'-
diaminobenzodine. Sections were lightly counterstained
with methyl green or hematoxylin. Selected slides were
stained with hemotoxylin and eosin to show morphology.
Quantification of immunopositive areas for pituitary 
hormones on Prop1 transgenic mouse pituitaries
Using immunohistochemical slides, individual pitui-
tary hormone (PRL, GH, ACTH, αGSU, TSHβ, LHβ and
FSHβ) positive cell areas and whole anterior pituitary areas
(as background) were counted by two independent observ-
ers. Five fields at 25× magnification were randomly selected
and counted using digital-image analyzing software, ImageJ
1.37v, developed at the National Institutes of Health,
Bethesda, MD, USA.
Laser microdissection and RT-PCR
Tissue sections of 8 μm thickness were prepared from
the same formalin fixed paraffin embedded tissue blocks and
counterstained with toluidine blue. For the separation of the
adenomas or hyperplastic cells in the Prop1 Tg pituitary sec-
tions, a laser capture assay was performed using a Laser
Capture Microdissection system (LCM) (MMI Molecular
Machines & Industries Inc, Rockledge, FL). Total RNA
extraction was performed using TRIzol reagent (Invitrogen
Life Technologies, Carlsbad, CA), and RNA was reverse
transcribed using the SuperScript First-Strand Synthesis
System RT-PCR kit (Invitrogen Life Technologies) after
incubation with proteinase K. RNase inhibitor (RNasin),
SuperScript III reverse transcriptase, RNase-free DNase I
and oligo (dT)12–18 primers were from Invitrogen Life Tech-
nologies. PCR was performed with AmpliTaq Gold PCR
kits according to the manufacturer’s instructions, and each
specific primer used was as follows: mouse PRL primers,
5'-AGC CCC CGA ATA CAT CCT AT-3' and 5'-ATC
CCA TTT CCT TTG GCT TC-3'; mouse GH primers, 5'-
TCC TCA GCA GGA TTT TCA CC-3' and 5'-CAT GTT
GGC GTC AAA CTT GT-3' and mouse GAPDH primers,
5'-TGC GAC TTC AAC AGC AAC TC-3' and 5'-ATG TAGPituitary Changes in Prop1 Transgenic Mice 49
GCC ATG AGG TCC AC-3'. These primer sets were
designed to span one intron to allow distinction of genomic
contamination. cDNA samples for PCR were incubated for
50 cycles of PCR amplification on a Mastercycler thermal
cycler (Eppendorf AG, Hamburg, Germany). The Prl,
Gh and Gapdh PCR products were detected as bands of
117 bp, 173 bp and 143 bp, respectively. Moreover, quanti-
tative PCR was performed using TaqMan Gene Expres-
sion Assays according to the manufacturer’s instructions
(Applied Biosystems, Foster City, CA). The TaqMan
probes for Mouse Prop1 (Mm00839471_m1) and b-actin
(Mm00607939_s1) were obtained from Applied Biosys-
tems. Quantitative real-time PCR was run for 50 cycles on
an ABI Prism 7700 thermal cycler (Applied Biosystems).
III. Results
Changes in body weight and pituitary weight in Prop1 
transgenic mice
Prop1 transgenic mice were generated with mouse
Prop1 genomic sequences under the control of the Cga pro-
moter, which is active in the progenitor cells of Rathke’s
pouch from e9.5 to e12.5 and, subsequently, activated in the
gonadotrope and TSH producing cell (thyrotrope) [19]. Cer-
tain types of adenomas, hyperplastic and hypertrophic
change in the anterior pituitary gland, arose in Prop1 trans-
genic mice at 1.5 years of age (Fig. 1A). Two of seven males
and seven of thirteen female mice were the founders of the
Prop1 transgene population. The body weight of transgenic
males were similar or slightly greater than that of wild-type
(WT) males; however, the weight of the pituitary was
decreased (Fig. 1B, C). In contrast, no correlation between
body weight and pituitary weight in transgenic or control
female mice was observed.
Prop1 transgene expression increases the incidence of 
pituitary adenomas
Analysis of all sections from Prop1 transgenic pitui-
taries confirmed the presence of pituitary adenomas and
morphological changing in the anterior lobe of each gland.
To determine the characteristics of these diseased pitui-
taries, sections were stained by immunohistochemistry using
antibodies against each of the pituitary hormones. The
adenomas were present in the background of only female
pituitaries and in 5 out of 9 Prop1 transgenic mice (Table 1).
Two cases of PRL producing adenomas (PRLomas) and one
GH producing adenoma (GHoma) were observed (Fig. 2
b, c). Two cases exhibited focal acidophilic PRLomas under-
going angiogenesis. These tumors that produced PRL with-
out other hormones in the cytoplasm demonstrated high
vascularity (Fig. 2 b1–7). One GHoma with microvesicular
fat did not produce other hormones, and this tumor was not
vascularized (Fig. 2 c1–7). One case of a multihormonal
tumor that including both a gonadotropin (Gn)-PRL double
positive region (Gn-PRLoma) and a somatomammotroph
(GH-PRL double positive) cell region (GH-PRLoma) was
induced in a Prop1 transgenic pituitary (Fig. 2 d, Table 1
Tg No. 4). Moreover, one case of a small TSHβ and αGSU-
positive adenoma (TSHoma) was induced without other
pituitary hormones (Fig. 2 e). We designated these lesions
as “adenomas” because the production of single hormones
and/or nodules were featured in their pituitary pathology.
Fig. 1. Body and pituitary weights of aged transgenic mice. Two of seven male and seven of thirteen female mice were the founders of the Prop1
transgene population (A). In the male transgenic mice, body weights are significantly increased (B-left), while pituitary weights are decreased
(C-left) when compared to that of WT mice. On the other hand, body and pituitary weights show no significant change in female transgenic
mice (Tg) (B, C-right). WT, wild-type mice; Tg, Cga-Prop1 Tg; Gray diamond, data from WT; white circle, data from Prop1 Tg.Egashira et al. 50
Each adenoma expresses specific transcription factors
In order to further characterize these adenomas, sec-
tions were immunostained with specific antibodies against
Pit1 (Fig. 3 a–e1) and ERα (Fig. 3 a–e2). Pit1 and ERα were
both detected in the PRLoma and the multihormonal tumor
(Gn-PRLoma/GH-PRLoma) (Fig. 3 b1, b2, d1, d2). In the
GHoma, ERα expression was weakly positive compared
with the surrounding region of the nodule (Fig. 3 c2). Gata2
was expressed in the nucleus of small TSHoma cells (Fig. 3
e2).
The Prl and Gh mRNA expression levels are different in 
Prop1 transgenic adenomas
To confirm the results of the immunohistochemistry
and image analyses, Prl and Gh mRNA accumulation in the
adenomatous regions (Fig. 4A-d and h) was compared with
the surrounding region (Fig. 4A-c and g) by laser microdis-
section (Fig. 4B). RT-PCR products of Prl and Gh mRNA
were identified as 117 bp and 173 bp bands on 2% agarose
gels, respectively. Prl expression was detected in all cases,
except the GHoma (Fig. 4B, top). We observed Gh expres-
sion in WT pituitaries, GHoma and the surrounding pituitary
regions of PRLoma, but Gh mRNA was not detected in the
PRLoma (Fig. 4B, middle). These RT-PCR results are con-
sistent with the patterns obtained by immunohistochemistry.
Prop1 expression in adenomas and these surrounding 
pituitaries
To quantify the expression of Prop1 relative to the
house-keeping gene β-actin, real-time RT-PCR was per-
formed using TaqMan probes for Prop1. No Prop1 expres-
sion was detected in matched WT animals. Prop1 expression
was elevated in the surrounding pituitaries of adenomas
compared with the WT pituitaries. Prop1 expression, how-
ever, was not observed in any adenoma nodules of Prop1
transgenic mice (Fig. 4C).
Signet-ring like hypertrophic cells are gonadotropes
Four of nine transgenic pituitaries had regions of wide-
spread hypertrophic signet-ring cells that were not present in
non-transgenic controls (Fig. 5 H&E, Table 1, Tg No. 6–9).
The pituitary signet-ring cells included one or two nuclei.
αGSU, LHβ and FSHβ were diffusely immunopositive in
the cytoplasm of pituitary signet-ring cells (data not shown
in FSHβ). However, these immunoreactivities were weaker
than those in non-disease pituitary gonadotroph cells. ERα
was expressed, but Pit1 was not expressed in the pituitary
signet-ring cells (Fig. 5, arrow).
Prop1 transgene expression induces hyperplastic changes 
in the surrounding anterior pituitaries of adenomas and of 
pituitary signet-ring cells
We also compared the hormone-positive areas of WT
pituitaries with the surrounding pituitary cells of the ade-
nomas or the pituitary signet-ring cells (as detected by
immunostaining) in the Prop1 transgenic pituitaries. This
was performed using digital-image analyzing software. In
the surrounding region of the Tg pituitary gland, which con-
tained GHoma, the GH-positive areas were approximately
1.8-fold larger than those of WT pituitaries or those of the
Tg pituitary containing PRLoma (Fig. 6A). PRL positive
areas in Prop1 Tg with GHoma or PRLoma were 2-fold
larger than WT pituitary (Fig. 6B). LHβ positive areas were
about 1.8-fold larger than WT pituitaries in the pituitaries
which contained signet-ring cells (Fig. 6F). In contrast,
ACTH positive areas in both Prop1 transgenic adenomas
were similar to those in the WT pituitary. In the surround-
ing region of small TSHoma, TSH positive areas were
Table 1. Diagnosis for Prop1 transgenic pituitary diseases
*Gn-PRLoma; Gonadotropin and PRL producing adenoma.
**GH-PRLoma; Somatomammotroph adenoma.
***signet-ring; Pituitary signet-ring cells.
Immunoreactivity: −; negative, +; less intense, ++; moderate, +++; intense.
Tg No. sex diagnosis
Hormones and Transcription factors in Prop1 transgenic pituitaries
GH PRL αGSU TSHβ LHβ FSHβ ACTH Pit1 ER GATA2 SF1
1 f PRLoma − + + + −−−−− + + + + + + −−
2 f PRLoma − + + −−−−− + + + + + +−
3f G H o m a + + −−−−−− + + + +−−
4 f Gn-PRLoma* −+ + + −++−++−−
GH-PRLoma** + + + + −−−−−+++−
5 f TSHoma −−+ + + + −−−+− + + −
6 m signet-ring*** −− + + −++−−+−−
signet-ring −− + + −+−−−+−−
7 m signet-ring −− + + −++−−+−−
signet-ring −−−−++−−+−−
8 f signet-ring −− + + −++−−+−−
9 f signet-ring −−−−++−−+−−Pituitary Changes in Prop1 Transgenic Mice 51
Fig. 2. Immunocharacterization of pituitary hormones in Prop1 transgenic adenomas. Light microscopy of coronal sections of a wild-type
mouse pituitary (WT; a) and Prop1 Tg mice including PRLoma (b), Prop1 Tg including GHoma (c), Gn-PRLoma/GH-PRLoma (d) and small
TSHoma (e). Immunostaining of GH, PRL, ACTH, αGSU, TSHβ, LHβ and H&E stain. All sections were stained by methyl green nuclear stain.
Asterisk: adenoma region. Bars=50 μm.Egashira et al. 52
Fig. 3. Immunocharacterization of transcription factors in Prop1 transgenic adenomas. Light microscopy of coronal sections of a wild-type
mouse pituitary (WT; a) and Prop1 Tg mice including PRLoma (b), Prop1 Tg including GHoma (c), Gn-PRLoma/GH-PRLoma (d) and small
TSHoma (e). Immunostaining of Pit1, ERα, Gata2 and H&E stain. Arrowhead: Gata2 expression in the nucleus of small TSHoma region,
Asterisk: adenoma region. Bars=50 μm.
Fig. 4. RT-PCR analysis of Prl, Gh and Prop1 expression in PRLomas and GHoma sampled by laser microdissection (LCM). Dividing between
the adenoma and non-diseased pituitary by LCM (A). PRLoma (a–d) and GHoma (e–h) were identified in different Prop1 Tg. All sections were
stained by H&E (a, e) and toluidine blue (b, f). Tissues were divided into adenomatous nodules (d, h) or these surrounding pituitary regions (c,
g) by LCM. RT-PCR analysis of Gh and Prl (B). mRNA from LCM samples was reverse transcribed. RT-PCR analysis reveals Prl (117 bp), Gh
(173 bp) and Gapdh (143 bp) fragments. The Cga-Prop1 Tg does not express Gh mRNA in PRLoma, nor Prl mRNA in GHoma, in agreement
with the results of immunohistochemistry (Fig. 2). Quantitative RT-PCR analysis of Prop1 expression (C). Prop1 mRNA expressions were
analyzed by quantitative RT-PCR. Prop1 is expressed in the hyperplastic surrounding regions of the adenomas. Prop1 expression is not
observed in PRLoma and GHoma. M, 50 bp ladder marker; WT, wild-type; Tg (PRL), Prop1 Tg with PRLoma; Tg (GH), Prop1 Tg with
GHoma; S, surrounding anterior pituitary region of adenoma; A, adenoma; Positive control, cDNA from normal fresh mouse pituitary; Negative
control, non-template control.Pituitary Changes in Prop1 Transgenic Mice 53
smaller than those observed in WT pituitaries (Fig. 6E).
αGSU-, TSHβ- and LHβ-positive areas in neoplastic pitu-
itaries were less than that of WT pituitary (Fig. 6D, E). We
described these pituitary changes as transgenic pituitary
adenomas as “hyperplasia”.
IV. Discussion
In the present study, mice overexpressing Prop1 under
the control of the Cga promoter tended to develop pituitary
adenomas. Persistent Prop1 expression has been shown to
induce tumors with non-hormonal nodules or a TSH-pro-
ducing adenoma in aged Tg mice [6]. Moreover, Prop1 is
also expressed in the dorsal area of Rathke’s pouch, which
was shown to be a proliferating region in mouse pituitary
development [30]. Here, we report that all Prop1 transgenes
clearly induced pituitary adenomas or the pituitary signet-
ring cells. Therefore, these results suggest that persistent
Prop1 overexpression may lead to dysregulated pituitary
cell proliferation and function.
Prop1 binds to early enhancer sites of the Pit1 gene
[10]. Pit1 is a critical regulator of GH production and
somatotroph cell differentiation [11, 20, 23]. In our study,
the PRLoma in the Prop1 Tg pituitary was vascularized in
a manner similar to the estrogen-inducible PRL-producing
tumors in rodents [12]. Estrogen may act directly through
ERα and β, and regulate expression of the pituitary tumor-
derived transforming gene (Pttg), which is known as an
angiogenic mechanism in pituitary tumors. Pttg expression
coincides with the early lactotrophic hyperplastic response,
angiogenesis and PRLoma development [13]. Together,
these results suggest that PRLomas form synchronously
with angiogenesis in the development of tumorigenesis in
Prop1 Tg pituitary.
Transcription factors and synergistic co-factors, includ-
ing Prop1, Pit1, Gata2 [4, 7], Sf1 [45], Tpit [40] and several
hypothalamic releasing hormone receptors [18, 22], are re-
quired for the determination of cell phenotypes and lineage-
specific cell proliferation. PRL expression and lactotroph
cell differentiation are regulated by the synergistic effects of
Pit1 and ERα [33, 44]. According to our immunohistochem-
ical data, PRLomas of aged Prop1 Tg were positive for both
Pit1 and ERα. GHoma in a Prop1 Tg was Pit1-positive, but
only very weakly ERα immunoreactive in our study. Activa-
Fig. 5. Characterization of ‘pituitary signet-ring cells’ in Prop1 transgenic pituitary. H&E stain, immunostaining of GH, PRL, αGSU, TSHβ,
LHβ, ACTH, Pit1 and ERα. All sections were counter-stained by methyl green or hematoxylin nuclear stain. Four cases of Prop1 Tg pituitaries
reveal signet-ring hypertrophic gonadotropes. Arrow: pituitary signet-ring cells, white arrowhead: nuclei of signet-ring cells. Bars=50 μm.Egashira et al. 54
tion of the Prop1-Pit1-ERα or Prop1-Pit1 sequence may cor-
relate to the differentiation of PRL- or GH-producing ade-
noma, respectively [5]. Pit1 and Gata2 were expressed in the
nucleus of a small TSHoma (Fig. 3 e1, 2). Synergic function
of Pit1 and Gata2 leads the expression of TSHβ [7, 24]. In
human growth hormone-releasing hormone (hGHRH) Tg,
Pit1 overexpression has been suggested to result in ade-
nomas through a “hyperplasia-adenoma” sequence [26, 38].
The regions of both GH-producing cells in the surrounding
pituitary regions of GHomas and PRL-producing cells in
the surrounding pituitary regions of PRLomas from Prop1
Tg pituitary was larger than that of WT pituitaries (Fig.
6A, B). Therefore, the surrounding pituitary cells of these
adenomas were thought to be at an early stage in the “hyper-
plasia-adenoma” sequence in Prop1 Tg. In the pituitary
signet-ring cells, the LHβ positive region was larger than
that of WT pituitaries (Fig. 6F), hence we designated this
as “hyperplasia” based on pituitary pathology. We suggest
that the tumorigenesis occurred during the transition from
normal to hyperplasia to adenoma in the Prop1 Tg pitui-
taries (Fig. 7).
Transcription factors are divided into two groups: tran-
scription factors involved in early development and tran-
scription factors involved in later functional differentiation.
Prop1 is included in both of these categories. Its expression
leads to the ontogenesis of pituitary gonadotropes, as well as
somatotropes, lactotropes, and caudomedial thyrotropes in
mouse studies [25, 42]. Additionally, as we report here,
Fig. 6. Quantification of hormone positive regions in the surrounding anterior pituitaries of adenomas and of pituitary signet-ring cells. Quan-
tification of immunopositive areas for individual pituitary hormones (A: GH, B: PRL, C: ACTH, D: αGSU, E: TSHβ and F: LHβ) were
measured using ImageJ analyzer. Data were normalized to areas of the surrounding pituitaries of the adenomas or the signet-ring gonado-
tropes in the same field (relative values vs. WT) from Prop1 Tg pituitaries. WT, wild-type mouse pituitary; Tg(PRL), surrounding region of
Prop1 Tg PRLoma; Tg(GH), surrounding region of Prop1 Tg GHoma; Tg(Gn/GH-PRL), surrounding region of Prop1 Tg Gn-PRLoma/GH-
PRLoma case; Tg(TSH), surrounding region of Prop1 Tg TSHoma; signet-ring, surrounding region of signet-ring gonadotroph cells.Pituitary Changes in Prop1 Transgenic Mice 55
Prop1 has a role not only in tumorigenesis, but also in pitu-
itary cell differentiation in the Prop1 Tg model.
αGSU is one of the earliest markers of anterior pitu-
itary development. The Prop1 positive ventral pituitary re-
gion is known to differentiate as other hormone-producing
quiescent cells arise with pituitary development [35]. In
PRLoma or GHoma of the Prop1 Tg mice, there was no
expression of Prop1 mRNA. Prop1 transgene expression is
dependent on Cga promoter activation in these mice, but
this may be attenuated with progression of monohormonal
(PRL or GH-producing) adenomatous differentiation. How-
ever,  αGSU was expressed in small TSHoma and Gn-
PRLoma. Prop1 is thought to be a critical initiation factor
for Pit1 lineage differentiation. It is known that GH- and
PRL-cell differentiations are induced after TSH-cell differ-
entiation in the Pit1 lineage [29]. The absence of Prop1 may
be induced after differentiation of the TSH lineage and Gn
cell lineage in the Prop1 Tg pituitary.
In half of all Prop1 Tg mice, pituitary signet-ring cells
were observed and expressed gonadotropins consisting of
αGSU, LHβ and FSHβ. The signet-ring cells also expressed
the transcription factor, ERα, without Gata2 and Sf1. It is
indicated that the pituitary signet-ring cells occur in the
gonadotropin producing cells, but may not be typical
because Gata2 and Sf1 are known to activate the expression
of gonadotropic hormones [4, 45]. These signet-ring cells
are morphologically similar to those of typical castration
cells [2, 14]. The possibilities include that these changes
may be interpreted to be due to the feedback response to
the physiologically gonadectomized condition of the aged
Prop1 Tg mice. It has been also reported that the signet-
ring changes may also be associated with tumor behavior
such as invasion [9]. Interestingly, the signet-ring cells were
prominent in two human pituitary adenoma cases, GHoma
and clinically non-functioning adenoma [9, 17]. Further
ultrastructural studies are necessary to clarify the character
of the pituitary signet-ring cells in Prop1 Tg mice.
In summary, based on these experimental studies, we
propose that constitutively expressed Prop1 contributes to
the development of Pit1-lineage adenomas (PRLoma,
GHoma and TSHoma) in Prop1 Tg female mice through
the “normal-hyperplasia-adenoma” sequence only. PRL and
GH differentiation may be dependent on activation by a
Pit1-ERα combination or Pit1 only, respectively, while TSH
differentiation may be dependent on the synergistic function
between Pit1 and Gata2. Prop1 may be related to the differ-
entiated Pit1-lineage adenoma and the levels of expression
may act as a critical regulator of Pit1-lineage hormones
since PRL expression depends on ERα and TSHβ expres-
sion depends on Gata2 [41]. In addition, persistent Prop1 ex-
pression led to the development of a multihormonal ade-
noma (Gn-PRLoma/GH-PRLoma). Thus, we conclude that
Prop1 acts as an important proliferation and differentiation
factor in the hyperplasia-adenoma and the hyperplasia-
pituitary signet-ring cell sequence in pituitary cells of
Prop1 Tg. The absence of Prop1 in adenomas and the for-
mation of pituitary signet-ring cells remain for further
investigation.
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Fig. 7. A scheme of the hyperplasia-adenoma sequence and the formation of signet-ring cells in Prop1 transgenic mouse pituitary. Tumori-
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